3,467 reports of this reaction
3.0% of all OCTREOTIDE ACETATE reports
#3 most reported adverse reaction
FATIGUE is the #3 most commonly reported adverse reaction for OCTREOTIDE ACETATE, manufactured by Novartis Pharmaceuticals Corporation. There are 3,467 FDA adverse event reports linking OCTREOTIDE ACETATE to FATIGUE. This represents approximately 3.0% of all 115,420 adverse event reports for this drug.
OCTREOTIDE ACETATE has an overall safety score of 85 out of 100. Patients taking OCTREOTIDE ACETATE who experience fatigue should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
FATIGUE is a less commonly reported adverse event for OCTREOTIDE ACETATE, but still significant enough to appear in the safety profile.
In addition to fatigue, the following adverse reactions have been reported for OCTREOTIDE ACETATE:
The following drugs have also been linked to fatigue in FDA adverse event reports:
FATIGUE has been reported as an adverse event in 3,467 FDA reports for OCTREOTIDE ACETATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
FATIGUE accounts for approximately 3.0% of all adverse event reports for OCTREOTIDE ACETATE, making it one of the most commonly reported side effect.
If you experience fatigue while taking OCTREOTIDE ACETATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.